Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relevant nonmajor bleeding. RESULTS: The primary efficacy outcome occurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in the conventional-therapy group (relative risk, 0.84; 95% confidence interval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage points; 95% CI, -1.3 to 0.4). Apixaban was noninferior to conventional therapy (P<0.001) for predefined upper limits of the 95% confidence intervals for both relative risk (<1.80) and difference in risk (<3.5 percentage points). Major bleeding occurred in 0.6% of patients who received apixaban and in 1.8% of those who received conventional therapy (relative risk, 0.31; 95% CI, 0.17 to 0.55; P<0.001 for superiority). The composite outcome of major bleeding and clinically relevant nonmajor bleeding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the conventional-therapy group (relative risk, 0.44; 95% CI, 0.36 to 0.55; P<0.001). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Self-citationPulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Farrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Cited by
Items 601–700 of 1,003
Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review
Galanti, K., Marino, M. D., Mansour, D., Testa, S., Rossi, D., Scollo, C., Magnano, R., Pezzi, L., D’Alleva, A., Forlani, D., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508281 · Cited by 27
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 34
Treatment options for venous thromboembolism: lessons learnt from clinical trials
McRae, S. J. (2014) · Thrombosis Journal · doi:10.1186/s12959-014-0027-8 · Cited by 26
Loffredo, L., Perri, L., Ben, M. D., Angelico, F., & Violi, F. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1171-7 · Cited by 27
“(AMPLIFY and HOKUSAI studies [24, 26]).”
BackgroundPatil, T., & Lebrecht, M. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.015 · Cited by 26
Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
Wojtukiewicz, M. Z., Skalij, P., Tokajuk, P., Polityńska, B., Wojtukiewicz, A. M., Tucker, S. C., & Honn, K. V. (2020) · Cancers · doi:10.3390/cancers12051144 · Cited by 24
Ma, G., Zhang, R., Wu, X., Wang, D., & Ying, K. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.02.008 · Cited by 25
“Apixaban is usually administrated with fix doses, as there is a rapid action onset as well as predictable pharmacokinetics, without extra laboratory monitoring [8].”
BackgroundPharmacology and Laboratory Testing of the Oral Xa Inhibitors
Samama, M. M., Meddahi, S., & Samama, C. M. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.06.009 · Cited by 26
Prins, M. H., & Lensing, A. W. A. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-13 · Cited by 25
“80 [28].”
The newer direct oral anticoagulants: a practical guide
Thachil, J. V. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-2-165 · Cited by 25
Developments in the management and treatment of pulmonary embolism
Limbrey, R., & Howard, L. (2015) · European Respiratory Review · doi:10.1183/16000617.00006614 · Cited by 28
Lusk, K. A., Snoga, J. L., Benitez, R. M., & Sarbacker, G. B. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017707126 · Cited by 26
“6% and a minor bleeding risk of up to 14% per year.(1-20) Dabigatran is indicated in treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), stroke prevention in nonvalvular atrial fibrillation, and prophylaxis of DVT and PE following hip replacement surgery.”
BackgroundIncorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics
Mohammad, I., Korkis, B., & Garwood, C. L. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1991 · Cited by 29
Bartoli-Abdou, J., Patel, J. P., Crawshaw, J., Vadher, B., Brown, A. H., Roberts, L. N., Patel, R., Arya, R., & Auyeung, V. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2017.12.021 · Cited by 24
Treatment Failures of Direct Oral Anticoagulants
Kajy, M., Mathew, A., & Ramappa, P. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001083 · Cited by 27
Dentali, F., Minno, M. N. D. D., Gianni, M., Ambrosino, P., Squizzato, A., & Ageno, W. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-015-1249-x · Cited by 26
Racial and Ethnic Differences in Response to Anticoagulation: A Review of the Literature
Gibson, C. M., & Yuet, W. C. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019894142 · Cited by 25
Valeriani, E., Porreca, E., Weitz, J. I., Schulman, S., Candeloro, M., & Nisio, M. D. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14807 · Cited by 26
Self-citationWysokiński, W. E., Froehling, D. A., Houghton, D. E., McBane, R. D., Vlazny, D. T., Bott‐Kitslaar, D. M., Kuczmik, W., Sutkowska, K., Bator, K., Hodge, D. O., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13471 · Cited by 25
Advances in the diagnosis and management of acute pulmonary embolism
den Exter, P. L., van der Hulle, T., Klok, F. A., & Huisman, M. V. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50002-3 · Cited by 28
“In the Amplify study, apixaban (10 mg twice daily for one week, followed by 5 mg twice daily), was compared to standard therapy (LMWH for at least 5 days followed by warfarin) [76] in 5393 patients with acute VTE.”
MethodA review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?
Güler, E., Güler, G. B., Demır, G. G., & Hatipoğlu, S. (2015) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2015.6532 · Cited by 26
Erratum: Balancing ischaemia and bleeding risks with novel oral anticoagulants
Baber, U., Mastoris, I., & Mehran, R. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.204 · Cited by 24
Lanitis, T., Leipold, R., Hamilton, M., Rublee, D., Quon, P., Browne, C., & Cohen, A. T. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.020 · Cited by 23
“VTE creates a substantial burden on patients and health care systems.(1) VTE is a common cause of death in hospital patients, and the treatment of nonfatal VTE and related long-term morbidities is associated with considerable costs.”
BackgroundSelf-citationKarakasis, P., Ktenopoulos, N., Pamporis, K., Sagris, Μ., Σουλαϊδόπουλος, Σ., Gerogianni, M., Leontsinis, I., Giannakoulas, G. A., Tousoulis, D., Fragakis, N., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133784 · Cited by 26
Dobesh, P. P., & Fanikos, J. R. (2014) · Drugs · doi:10.1007/s40265-014-0301-x · Cited by 24
“Both the RE-COVER and AMPLIFY trials had treatment durations of 6 months [14, 15, 18].”
BackgroundMethodInfluentialRoetker, N. S., Lutsey, P. L., Zakai, N. A., Alonso, Á., Adam, T. J., & MacLehose, R. F. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1668521 · Cited by 23
“(4) an observational study of unprovoked VTE in Denmark (2.”
BackgroundCloney, M. B., Goergen, J. A., Hopkins, B. S., Dhillon, E. S., & Dahdaleh, N. S. (2018) · Journal of Neurosurgery Spine · doi:10.3171/2018.5.spine171027 · Cited by 23
Moraes, A. A. D. A., & Conforto, A. B. (2022) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2022-s108 · Cited by 27
Venous thromboembolism mortality and trends in older US adults, 2011–2019
Giorgio, K., Walker, R. F., MacLehose, R. F., Herrera, D. A., Wang, W., Alonso, Á., Zakai, N. A., & Lutsey, P. L. (2023) · American Journal of Hematology · doi:10.1002/ajh.26996 · Cited by 25
Spandorfer, J. M., & Galanis, T. (2015) · Annals of Internal Medicine · doi:10.7326/aitc201505050 · Cited by 26
A new paradigm shift in antithrombotic therapy
Pudusseri, A., Shameem, R., & Spyropoulos, A. C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00133 · Cited by 25
Barbar, S., Milan, M., Campello, E., Spiezia, L., Piovella, C., Pesavento, R., & Prandoni, P. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-04-0396 · Cited by 26
“The results of several randomised clinical trials suggest that these drugs have a favorable benefit-to-risk profile in the first 6-12 months after an episode of VTE in comparison with conventional treatment (60-65).”
BackgroundIhaddadene, R., & Carrier, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1120718 · Cited by 23
“A subgroup evaluation of the AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as FirstLine Therapy) trial showed a reduction in major bleeding events in the apixaban group compared to the warfarin group in patients weighing >100 kg.[88] Given the paucity of data in the patien…”
MethodNoble, S., & Sui, J. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30115-3 · Cited by 24
Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension
Gabriel, L., Delavenne, X., Bedouch, P., Khouatra, C., Bouvaist, H., Cordier, J.-F., Mornex, J., Pison, C. M., Cottin, V., & Bertoletti, L. (2016) · Respiration · doi:10.1159/000445122 · Cited by 23
Apixaban: A Review in Venous Thromboembolism
Greig, S. L., & Garnock-Jones, K. P. (2016) · Drugs · doi:10.1007/s40265-016-0644-6 · Cited by 26
“AMPLIFY and AMPLIFY-J were active comparatorcontrolled trials that enrolled patients with objectively confirmed, acute, symptomatic VTE [32, 34], and AMPLIFY-EXT was a placebo-controlled trial that included patients who had completed 6–12 months’ treatment with standard anticoagulant therapy for objectively confirmed,…”
BackgroundInfluentialde Jong, L. A., Dvortsin, E., Janssen, K. J. M., & Postma, M. J. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.12.012 · Cited by 23
“292 assumed to be equal across treatments.(8,9) After treatment cessation, lifetime risk of RecVTE was calculated from the cumulative 10-year incidence at 39.”
BackgroundMethodResultInfluentialThe effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
Frost, C. E., Song, Y. J., Yu, Z., Wang, J. J. J., Lee, L., Schuster, A. E., Pollack, A., & LaCreta, F. P. (2017) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s115687 · Cited by 27
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide
Shatzel, J. J., Daughety, M. M., Olson, S. R., Beer, T. M., & DeLoughery, T. G. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.022004 · Cited by 23
“001).(19,20) Apixaban has several potential interactions with enzalutamide that makes simultaneous use of these agents potentially challenging.”
BackgroundUpdate on extended treatment for venous thromboembolism
Peñaloza-Martínez, E., Rodríguez, P. D., Proietti, M., Fernández‐Llamazares, G. S., Mendo, C. L., Álvarez-Sala, J. L., Marra, A. M., & del Toro‐Cervera, J. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1538564 · Cited by 26
“The AMPLIFY-EXT trial [33] compared apixaban at 2 different doses (2.”
MethodLee, J. H., Hyun, D., Choi, C., Lee, J. C., Kim, W. S., Oh, Y., Lee, S., & Lee, J. S. (2019) · Respiration · doi:10.1159/000499895 · Cited by 23
Korobey, M. J., Sadaka, F. G., Javed, M. A., Moynihan, M., & Alsaei, A. (2020) · Neurocritical Care · doi:10.1007/s12028-020-00968-6 · Cited by 23
Wik, H. S., Kahn, S. R., Eriksson, H., Morrison, D., Ghanima, W., Schulman, S., & Sandset, P. M. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15449 · Cited by 24
Immunotherapy in antiphospholipid syndrome
López-Pedrera, C., Aguirre, M. A., Ruiz‐Limón, P., Pérez‐Sánchez, C., Jiménez, Y., Barbarroja, N., & Cuadrado, M. J. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.06.006 · Cited by 24
Bleeding and clotting in hereditary hemorrhagic telangiectasia
Dittus, C. E., Streiff, M., & Ansell, J. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i4.330 · Cited by 25
Cancer-associated thrombosis in Asia
Angchaisuksiri, P. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0110-4 · Cited by 26
Phillippe, H. M., Hornsby, L. B., Eudaley, S. T., Armstrong, E. M., & Bellone, J. M. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014530390 · Cited by 29
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
Robertson, L., & Kesteven, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010957 · Cited by 23
Amin, A., Jing, Y., Trocio, J., Lin, J., Lingohr-Smith, M., & Graham, J. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.950670 · Cited by 22
Sindet-Pedersen, C., Pallisgaard, J. L., Olesen, J. B., Gislason, G. H., & Arevalo, L. C. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.022 · Cited by 22
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy
Finks, S. W., Trujillo, T. C., & Dobesh, P. P. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016632785 · Cited by 24
“Patients on dual antiplatelet or daily low-dose aspirin were excluded from the AMPLIFY program.(38,48) Therefore, the impact of these agents on the efficacy and safety of the DOACs in VTE treatment has not yet been determined.”
InfluentialNonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
Brown, K. S., Zahir, H., GROSSO, M. A., Lanz, H., Mercuri, M. F., & Levy, J. H. (2016) · Critical Care · doi:10.1186/s13054-016-1422-2 · Cited by 27
Efficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism
Ghazvinian, R., Gottsäter, A., & Elf, J. L. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1607-9 · Cited by 24
Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia
Kar, S., Mottamal, M., & Al‐Horani, R. A. (2020) · ChemistryOpen · doi:10.1002/open.202000277 · Cited by 23
Kim, H. Y., Chang, S., Kim, K. H., Kim, J. Y., Seo, W., Kim, H., Seo, J.-S., Shin, S., Rhee, S. J., Lee, S. H., et al. (2021) · Journal of Cardiovascular Imaging · doi:10.4250/jcvi.2021.0014 · Cited by 24
Kline, J. A., Adler, D. H., Alanis, N., Bledsoe, J. R., Courtney, D. M., d’Etienne, J. P., Diercks, D. B., Garrett, J. S., Jones, A. E., MacKenzie, D. C., et al. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007600 · Cited by 26
Fukasawa, T., Seki, T., Nakashima, M., & Kawakami, K. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15799 · Cited by 24
Talasaz, A. H., Sadeghipour, P., Ortega‐Paz, L., Kakavand, H., Aghakouchakzadeh, M., Beavers, C. J., Fanikos, J. R., Eikelboom, J. W., Siegal, D. M., Monréal, M., et al. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01003-3 · Cited by 24
“…with VTE, GIB events were more frequent with dabigatran than with warfarin (4.2% versus 2.8% in the RE-COVER I RCT 136 and 3.7% versus 2.6% in the RE-COVER II RCT 137 ), whereas GIB events were less frequent with apixaban than with warfarin (0.3% versus 0.7% in the AMPLIFY trial 138 ) (Fig.”
InfluentialDiagnosis and treatment of acute pulmonary embolism
Widimsky, J., Jr. (2013) · Cor et Vasa · doi:10.1016/j.crvasa.2013.10.001 · Cited by 22
Tomkowski, W. Z., Kuca, P., Urbanek, T., Chmielewski, D., Krasiński, Z., Pruszczyk, P., Windyga, J., Oszkinis, G., Jawień, A., Burakowski, J., et al. (2017) · Acta Angiologica · doi:10.5603/aa.2017.0008 · Cited by 27
Evaluation of direct oral anticoagulants and vitamin K antagonists in mesenteric venous thrombosis
Salim, S., Ekberg, O., Elf, J. L., Zarrouk, M., Gottsäter, A., & Acosta, S. (2018) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355518779517 · Cited by 24
It's time for head-to-head trials with direct oral anticoagulants
Tritschler, T., & Castellucci, L. A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.019 · Cited by 24
Yamashita, Y., Yoshikawa, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.06.032 · Cited by 25
Devata, S., Angelini, D. E., Blackburn, S. A., Hawley, A. E., Myers, D. D., Schaefer, J. K., Hemmer, M. V., Magnani, J. L., Thackray, H. M., Wakefield, T. W., et al. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12279 · Cited by 23
Powell, M. Z., de Villers, K. T., Schwarz, K. A., Case, D. E., & Trujillo, T. C. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020952749 · Cited by 23
Huang, H., Peng, C. C., Lin, S., Munir, K. M., Chang, R. H., Wu, B., Liu, P. P., Hsu, J., Loh, C., & Tu, Y. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019618 · Cited by 23
Ceresetto, J. M. (2016) · Clinics · doi:10.6061/clinics/2016(01)07 · Cited by 25
“The results of key studies of each of the DOACs are summarized in Table 2 (64-71).”
BackgroundFrost, C. E., Shenker, A., Jhee, S. S., Yu, Z., Wang, J. J. J., Bragat, A., Pursley, J. M., & LaCreta, F. P. (2018) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s169505 · Cited by 26
Direct-Acting Oral Anticoagulants in Critically Ill Patients
Rali, P. M., Gangemi, A. J., Moores, A., Mohrien, K. M., & Moores, L. K. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.05.025 · Cited by 24
Pedersen, M. H., Wahlsten, L. R., Grønborg, H., Gislason, G., Petersen, M. M., & Bonde, A. N. (2019) · The American Journal of Sports Medicine · doi:10.1177/0363546519876054 · Cited by 27
Robertson, L., & Kesteven, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956 · Cited by 22
Fredman, D., McNeil, R., Eldar, O., Leader, A., Gafter-Gvili, A., & Avni, T. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02926-3 · Cited by 21
“Randomized controlled trials (RCTs) that compared DOACs to low molecular weight heparin (LMWH) and vitamin K antagonists (VKA) have shown DOACs to be of comparable efficacy alongside a preferable safety profile [4, 5].”
Bromley, A., & Plitt, A. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0107-0 · Cited by 21
“The results of AMPLIFY-EXT are limited by the patient characteristics of the study, principally the fact that only 15% of the patients studied were greater than 75 years of age and over 90% of patients had a creatinine clearance (CrCL) greater than 50 ml/min.”
InfluentialCohen, A. T., Berger, S. E., Milenković, D., Hill, N. R., & Lister, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.017 · Cited by 22
Self-citationAntiplatelets, anticoagulants, and colonoscopic polypectomy
Abraham, N. S. (2019) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2019.09.033 · Cited by 23
Ebraheem, M. S., Alzahrani, I., Crowther, M. A., Rochwerg, B. N., & Almakadi, M. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14949 · Cited by 22
Rodríguez, J., Kobus, V., Téllez, I. E. H., & Pérez, G. (2020) · Annals of The Royal College of Surgeons of England · doi:10.1308/rcsann.2020.0209 · Cited by 23
Zappulla, P., & Calvi, V. I. (2021) · TH Open · doi:10.1055/s-0041-1730035 · Cited by 23
Ballerie, A., Van, R. N., Lacut, K., Galinat, H., Rousseau, C., Pontis, A., Nédelec-Gac, F., Lescoat, A., Belhomme, N., Guéret, P., et al. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.10.009 · Cited by 21
Tijani, A., Coons, E. M., Mizuki, B., Dermady, M., Stanilova, K., Casey, A. L., Alqudsi, M., Gastañaduy, M., Elmayan, A., Bamnolker, A., et al. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221129348 · Cited by 21
Treating cancer-associated venous thromboembolism: A practical approach
Cutsem, E. V., Mahé, I., Felip, E., Agnelli, G., Awada, A. H., Cohen, A. T., Falanga, A., Mandalà, M., Peeters, M., Tsoukalas, N., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114263 · Cited by 21
Self-citationMerli, G. J., Hollander, J. E., Lefèbvre, P., Laliberté, F., Raut, M. K., Olson, W. H., & Pollack, C. V. (2015) · Hospital Practice · doi:10.1080/21548331.2015.1021659 · Cited by 21
“Recently, large international trials of non-VKA oral anticoagulant (NOAC) agents, including rivaroxaban, dabigatran, apixaban, and edoxaban, have shown comparable or superior efficacy and safety to the combination of LMWH/warfarin for the treatment of DVT [1,5-8].”
BackgroundTreatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants
Lee, A. Y. Y., & Carrier, M. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50027-8 · Cited by 26
“Cancer patients represented even a smaller subgroup in the AMPLIFY trial that compared apixaban monotherapy with enoxaparin and warfarin [23].”
BackgroundNew Oral Anticoagulants and Their Reversal Agents
Morotti, A., & Goldstein, J. N. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-016-0430-5 · Cited by 24
Beyer‐Westendorf, J., Lensing, A. W. A., Arya, R., Bounameaux, H., Cohen, A. T., Wells, P. S., Middeldorp, S., Verhamme, P. B., Hughes, R. J., Kucher, N., et al. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.11.014 · Cited by 21
“been published.[1-3] and were registered at ClinicalTrials.”
BackgroundSelf-citationUse of novel oral anticoagulant agents in venous thromboembolism
Madan, S., Shah, S., Dale, P., Partovi, S., & Parikh, S. A. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2016.11.17 · Cited by 23
“After all ADVANCE trials had been published, apixaban was evaluated for use in treatment of acute VTE in the Apixiban for the Initial Management of Pulmonary Embolism and Deep-Venous Thrombosis as First-Line Therapy (AMPLIFY) trial (Table 3) (31).”
MethodNovel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions
Nakamura, M., Yamada, N., & Ito, M. (2017) · Annals of Vascular Diseases · doi:10.3400/avd.ra.17-00015 · Cited by 24
Tarango, C., Schulman, S., Betensky, M., & Goldenberg, N. A. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1407241 · Cited by 21
“In the last decade, VTE treatment trials with the non-vitamin K direct oral anticoagulants (DOACs), which include oral direct thrombin inhibitors and Xa inhibitors, have demonstrated efficacy of these agents in secondary VTE prevention, with similar or better safety profiles than warfarin [32-35] DOACs have also been…”
BackgroundGroetzinger, L. M., Miller, T. J., Rivosecchi, R. M., Smith, R. E., Gladwin, M. T., & Rivera‐Lebron, B. N. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618755311 · Cited by 21
“daily life.(7,8) Clotting events were defined as new or recurrent deep venous thrombosis, PE, or another vascular event such as acute coronary syndrome or ischemic stroke.”
BackgroundInfluentialGrandoni, F., & Alberio, L. (2019) · Cancers · doi:10.3390/cancers11010046 · Cited by 23
“Apixaban was non-inferior compared to the standard of treatment in the rate of recurrence and in mortality, and was superior in the rates of bleeding in a total of 5395 patients enrolled in the AMPLIFY trial [31].”
BackgroundMethodKreutz, R. H., Mantovani, L. G., Haas, S. K., Monje, D., Schneider, J., Bugge, J., Gebel, M., Tamm, M., Ageno, W., & Turpie, A. G. G. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.02.010 · Cited by 24
Overcoming challenges of venous thromboembolism in sickle cell disease treatment
Ogunsile, F. J., Naik, R. P. P., & Lanzkron, S. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1583554 · Cited by 21
Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism
Quan, S., Smith, J. E., Wu, C. M., Koshman, S. L., Nguyen, B. V., & Bungard, T. J. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.01.011 · Cited by 22
Pompilio, G., Integlia, D., Raffetto, J. D., & Palareti, G. (2020) · TH Open · doi:10.1055/s-0040-1709731 · Cited by 21
Grundtvig, J. L. G., Ovesen, C., Havsteen, I. B., Christensen, T., Gaist, D., Iversen, H. K., Kruuse, C. R., Lilja‐Cyron, A., Ægidius, K. L., Rosenbaum, S., et al. (2021) · European Stroke Journal · doi:10.1177/23969873211008770 · Cited by 22
Merli, G. J., Hollander, J. E., Lefèbvre, P., Laliberté, F., Raut, M. K., Germain, G., Bookhart, B., & Pollack, C. V. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1096274 · Cited by 23
Amin, A., Bruno, A., Trocio, J., Lin, J., & Lingohr-Smith, M. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615585991 · Cited by 20
“As real-world observational studies have shown patient populations with VTE markedly differ from those participating in clinical trials, it is important to predict medical cost differences among patients with VTE receiving different treatments in real-world settings.(6-14,17,19) The study of Lefebvre et al, from which…”
BackgroundMethodResultInfluentialElbadawi, A., Shnoda, M., Mahmoud, K., & Elgendy, I. Y. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa067 · Cited by 20
Cardinal, R. M., D'Amico, F. J., D'Addezio, A. S., Dakers, K., & Castelli, G. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02361-8 · Cited by 20
Eighty years of oral anticoagulation: Learning from history
Montinari, M. R., Minelli, S., & Caterina, R. D. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106918 · Cited by 21
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- Pfizer (United States) (US)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-29
- Volume
- 369
- Issue
- 9
- Pages
- 799-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166402206
- Cited by
- 2,324
- References
- 13
- Citations by year
- 2026: 109 · 2025: 101 · 2024: 134 · 2023: 134 · 2022: 162 · 2021: 193 · 2020: 224 · 2019: 193 · 2018: 213 · 2017: 191 · 2016: 234 · 2015: 198 · 2014: 184 · 2013: 51
- FWCI
- 194.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, acute venous thromboembolism, factor Xa inhibitors, oral anticoagulation, enoxaparin, warfarin, recurrent venous thromboembolism, major bleeding, non-inferiority, fixed-dose regimen, direct oral anticoagulants, anticoagulation duration, venous thromboembolism
- MeSH terms
- Acute Disease, Administration, Oral, Adult, Aged, Anticoagulants, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Warfarin, Treatment Outcome, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.